血清维生素 D 作为小儿急性淋巴细胞白血病风险因素的潜在作用。

IF 1.2 4区 医学 Q4 HEMATOLOGY
Pediatric Hematology and Oncology Pub Date : 2024-01-01 Epub Date: 2023-07-21 DOI:10.1080/08880018.2023.2202687
Pardis Nematollahi, Sina Arabi, Marjan Mansourian, Saeed Yousefian, Alireza Moafi, Sayed Nassereddin Mostafavi, Amirmansour Alavi Naeini, Afshin Ebrahimi, Karim Ebrahimpour, Mohammad Mehdi Amin, Aryan Kavosh, Shirin Mahmoudi Kohi, Roya Kelishadi
{"title":"血清维生素 D 作为小儿急性淋巴细胞白血病风险因素的潜在作用。","authors":"Pardis Nematollahi, Sina Arabi, Marjan Mansourian, Saeed Yousefian, Alireza Moafi, Sayed Nassereddin Mostafavi, Amirmansour Alavi Naeini, Afshin Ebrahimi, Karim Ebrahimpour, Mohammad Mehdi Amin, Aryan Kavosh, Shirin Mahmoudi Kohi, Roya Kelishadi","doi":"10.1080/08880018.2023.2202687","DOIUrl":null,"url":null,"abstract":"<p><p>Vitamin D deficiency/insufficiency (VDD, VDI) is common in children yet limited experience exists on the association of VDD and hematologic malignancies amongst this population. Therefore, this study aimed to compare serum vitamin D levels in children with acute lymphoblastic leukemia (ALL) and controls. Moreover, vitamin D levels is compared in subjects with and without relapse and evaluated as a prognostic factor for relapse-free survival (RFS). Children with newly diagnosed ALL were recruited as case group. Data on demographic variables as well as the dietary habits were collected by interview. In addition, serum 25(OH)D3 was measured. The case group was followed up for 36 months to assess RFS. Overall, 358 subjects were included in the study (<i>n</i> = 169 cases, <i>n</i> = 189 controls). The mean levels of 25(OH)D3 were 28.05 ± 18.87 and 28.76 ± 12.99 in cases and controls, respectively (<i>p</i> = .68). VDD was found in 15.4% (<i>n</i> = 26) and 4.2% (<i>n</i> = 8) of the case and control groups, respectively (<i>p</i> < .001). Relapse was seen in 18.34% of patients and vitamin D levels of 20 ng/mL or above were associated with longer RFS (<i>p</i> = .044 by log-rank test). In this study, VDD and VDI amongst children with ALL were significantly higher than controls. In addition, lower levels of Vitamin D were associated with increased risk of relapse.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Potential role of serum vitamin D as a risk factor in pediatric acute lymphoblastic leukemia.\",\"authors\":\"Pardis Nematollahi, Sina Arabi, Marjan Mansourian, Saeed Yousefian, Alireza Moafi, Sayed Nassereddin Mostafavi, Amirmansour Alavi Naeini, Afshin Ebrahimi, Karim Ebrahimpour, Mohammad Mehdi Amin, Aryan Kavosh, Shirin Mahmoudi Kohi, Roya Kelishadi\",\"doi\":\"10.1080/08880018.2023.2202687\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Vitamin D deficiency/insufficiency (VDD, VDI) is common in children yet limited experience exists on the association of VDD and hematologic malignancies amongst this population. Therefore, this study aimed to compare serum vitamin D levels in children with acute lymphoblastic leukemia (ALL) and controls. Moreover, vitamin D levels is compared in subjects with and without relapse and evaluated as a prognostic factor for relapse-free survival (RFS). Children with newly diagnosed ALL were recruited as case group. Data on demographic variables as well as the dietary habits were collected by interview. In addition, serum 25(OH)D3 was measured. The case group was followed up for 36 months to assess RFS. Overall, 358 subjects were included in the study (<i>n</i> = 169 cases, <i>n</i> = 189 controls). The mean levels of 25(OH)D3 were 28.05 ± 18.87 and 28.76 ± 12.99 in cases and controls, respectively (<i>p</i> = .68). VDD was found in 15.4% (<i>n</i> = 26) and 4.2% (<i>n</i> = 8) of the case and control groups, respectively (<i>p</i> < .001). Relapse was seen in 18.34% of patients and vitamin D levels of 20 ng/mL or above were associated with longer RFS (<i>p</i> = .044 by log-rank test). In this study, VDD and VDI amongst children with ALL were significantly higher than controls. In addition, lower levels of Vitamin D were associated with increased risk of relapse.</p>\",\"PeriodicalId\":19746,\"journal\":{\"name\":\"Pediatric Hematology and Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08880018.2023.2202687\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2023.2202687","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

维生素 D 缺乏/不足(VDD、VDI)在儿童中很常见,但有关 VDD 与儿童血液系统恶性肿瘤之间关系的经验却很有限。因此,本研究旨在比较急性淋巴细胞白血病(ALL)患儿和对照组患儿的血清维生素 D 水平。此外,还比较了复发和未复发受试者的维生素D水平,并将其作为无复发生存期(RFS)的预后因素进行评估。研究人员招募了新诊断为ALL的儿童作为病例组。通过访谈收集有关人口统计学变量和饮食习惯的数据。此外,还测量了血清25(OH)D3。对病例组进行为期36个月的随访,以评估RFS。研究共纳入 358 名受试者(n = 169 例病例,n = 189 例对照)。病例组和对照组的 25(OH)D3 平均水平分别为 28.05 ± 18.87 和 28.76 ± 12.99(p = .68)。病例组和对照组中分别有 15.4% (n = 26)和 4.2% (n = 8)的人出现 VDD(经对数秩检验,P = .044)。在这项研究中,ALL患儿的VDD和VDI明显高于对照组。此外,维生素D水平较低与复发风险增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Potential role of serum vitamin D as a risk factor in pediatric acute lymphoblastic leukemia.

Vitamin D deficiency/insufficiency (VDD, VDI) is common in children yet limited experience exists on the association of VDD and hematologic malignancies amongst this population. Therefore, this study aimed to compare serum vitamin D levels in children with acute lymphoblastic leukemia (ALL) and controls. Moreover, vitamin D levels is compared in subjects with and without relapse and evaluated as a prognostic factor for relapse-free survival (RFS). Children with newly diagnosed ALL were recruited as case group. Data on demographic variables as well as the dietary habits were collected by interview. In addition, serum 25(OH)D3 was measured. The case group was followed up for 36 months to assess RFS. Overall, 358 subjects were included in the study (n = 169 cases, n = 189 controls). The mean levels of 25(OH)D3 were 28.05 ± 18.87 and 28.76 ± 12.99 in cases and controls, respectively (p = .68). VDD was found in 15.4% (n = 26) and 4.2% (n = 8) of the case and control groups, respectively (p < .001). Relapse was seen in 18.34% of patients and vitamin D levels of 20 ng/mL or above were associated with longer RFS (p = .044 by log-rank test). In this study, VDD and VDI amongst children with ALL were significantly higher than controls. In addition, lower levels of Vitamin D were associated with increased risk of relapse.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
5.90%
发文量
71
审稿时长
6-12 weeks
期刊介绍: PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信